Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Trial Profile

Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Fulranumab (Primary)
  • Indications Pain
  • Focus Registrational; Therapeutic Use
  • Acronyms PAI3003
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 04 Oct 2016 This trial was completed in Spain (end date: 2016-09-14), according to European Clinical Trials Database.
    • 22 Sep 2016 This trial has been discontinued in Netherlands as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top